Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular docking of novel 5-O-benzoylpinostrobin derivatives as wild type and L858R/T790M/V948R mutant EGFR inhibitor.

Journal of basic and clinical physiology and pharmacology - 19 Dec 2019

Pratama Mohammad Rizki Fadhil, Poerwono Hadi, Siswodihardjo Siswandono

Abstract excerpt

Background Previous studies have shown that 5-O-benzoylpinostrobin derivatives is a potential anti-breast cancer, with the highest potential being the HER2 inhibitors, is a protein's member of the epidermal growth factor receptor (EGFR) family. Overexpression of EGFR itself is known to be one of the causes of other cancer, including non-small cell lung cancer (NSCLC). Thus, it is possible that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ErbB Receptors
Share to Flavanones

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Molecular Docking Simulation

Share to Molecular Structure

Share to Mutation

Share to Protein Binding

Source

Identifiers

PMID: 31855568
DOI: 10.1515/jbcpp-2019-0301

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular docking of novel 5-O-benzoylpinostrobin derivatives as wild type and L858R/T790M/V948R mutant EGFR inhibitor.PMID 31855568Read ↗

Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles.Semantic proximity Read ↗

Investigating mutation-specific biological activities of small molecules using quantitative structure-activity relationship for epidermal growth factor receptor in cancer.Semantic proximity Read ↗

Protein-Ligand Based Pharmacophore Approach against ERK5 Involved in Breast Cancer; In-Silico Study of Flavonoids from Blighia sapidaSemantic proximity Read ↗

Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019).Semantic proximity Read ↗

Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.Semantic proximity Read ↗

Design and investigation of interactions of novel peptide conjugates of purine and pyrimidine derivatives with EGFR and its mutant T790M/L858R: an in silico and laboratory study.Semantic proximity Read ↗

Exploring acenocoumarol and silodosin as allosteric EGFR inhibitors for the treatment of non-small cell lung cancerSemantic proximity Read ↗

Towards identification of novel inhibitors of EGFR mutants through in-silico approach.Semantic proximity Read ↗

Structure-based virtual screening, pharmacokinetic prediction, molecular dynamics studies for the identification of novel EGFR inhibitors in breast cancerSemantic proximity Read ↗

Systematic analysis and molecular profiling of EGFR allosteric inhibitor cross-reactivity across the proto-oncogenic ErbB family kinases by integrating dynamics simulation, energetics calculation and biochemical assay.Semantic proximity Read ↗

Computational approaches for evaluation of isobavachin as potential inhibitor against t877a and w741l mutations in prostate cancer.Semantic proximity Read ↗

Virtual screening, XGBoost based QSAR modelling, Molecular Docking and Molecular Dynamics Simulation approach to discover a new inhibitor targeting ErbB1 ProteinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.